The company said net revenues for Q1 2025 were $2,652 million, up 12.1% from $2,366 million for Q1 2024, and reported diluted earnings per share of $1.94, up 12.8% year over year.

1. 01

   The company said net revenues for Q1 2025 were $2,652 million, up 12.1% from $2,366 million for Q1 2024, and reported diluted earnings per share of $1.94, up 12.8% year over year.

2. 02

   Quest Diagnostics said adjusted operating income for Q1 was $406 million (15.3% of net revenues) and adjusted diluted EPS was $2.21, up 8.3% from a year earlier. Adjusted measures are non-GAAP figures that exclude special items such as restructuring and integration charges and amortization expense.

3. 03

   The company said net cash provided by operating activities for Q1 2025 was $314 million, about 2 times the $154 million in the same quarter a year earlier. It said it borrowed $215 million and repaid $600 million of debt in the quarter, and cash and cash equivalents were $188 million as of March 31.

4. 04

   The company said it reaffirmed its 2025 full-year net revenue outlook of $10.70 billion to $10.85 billion and its adjusted diluted EPS outlook of $9.55 to $9.80. Its reported diluted EPS outlook changed to $8.62 to $8.87 from $8.34 to $8.59.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.